Pemphigus Vulgaris Market Trends Shaped by New Drug Uptake

Pemphigus Vulgaris Market Size, Key Players with Trends and Dynamics

The global pemphigus vulgaris market size is calculated at US$ 530.43 million in 2025, grew to US$ 574.19 million in 2026, and is projected to reach around US$ 1171.93 million by 2035. The market is expanding at a CAGR of 8.25% between 2026 and 2035.

The pemphigus vulgaris market is mostly being driven by an increase in cases of immune system dysfunction, where antibodies target the proteins that hold skin cells together. The market is also expanding due to the increased use of different drugs, including penicillamine, angiotensin-converting enzyme inhibitors, and nonsteroidal anti-inflammatory drugs, which can cause the illness. A positive outlook for the market is also being created by the widespread use of immunosuppressive medications in conjunction with corticosteroids to regulate the immune system and stop the development of new blisters.

Key Takeaways

• Pemphigus vulgaris industry poised to reach USD 574.19 million by 2026.
• Forecasted to grow to USD 1171.93 million by 2035.
• Expected to maintain a CAGR of 8.25% from 2026 to 2035.
• North America dominated the pemphigus vulgaris market in 2024.
• Asia Pacific is expected to grow at the fastest CAGR during the forecast period.
• By drug class, the corticosteroids segment dominated the market in 2024.
• By drug class, the biologic therapies segment is expected to grow at the fastest CAGR during the forecast period.
• By treatment type, the first-line therapy segment dominated the market in 2024.
• By treatment type, the combination therapy segment is expected to grow at the fastest CAGR during the forecast period.
• By route of administration, the oral segment dominated the pemphigus vulgaris market in 2024.
• By route of administration, the intravenous segment is expected to grow at the fastest CAGR during the forecast period.
• By distribution channel, the hospital pharmacies segment dominated the market in 2024.
• By distribution channel, the online pharmacies segment is expected to grow at the fastest CAGR during the forecast period.
• By end-user, the hospitals segment dominated the pemphigus vulgaris market in 2024.
• By end-user, the specialty dermatology clinics segment is expected to grow at the fastest CAGR during the forecast period.

Key Indicators and Highlights

What is Pemphigus Vulgaris?

The global pemphigus vulgaris market includes pharmaceutical therapies, biologics, immunosuppressants, diagnostics, and supportive care solutions used for the treatment and management of pemphigus vulgaris, a rare autoimmune blistering disorder of the skin and mucous membranes.

The market covers corticosteroids, monoclonal antibodies, immunoglobulins, plasmapheresis, hospitalization services, and long-term disease management. Growth is driven by rising diagnosis rates, increasing awareness of rare autoimmune diseases, advancements in biologic therapies, improved access to specialty dermatology care, and expanding clinical research pipelines.

Pemphigus Vulgaris Market Outlook

• Global Expansion: The global market for Pemphigus Vulgaris treatments is undergoing significant expansion, driven by increasing awareness and diagnostic advancements. North America leads due to robust healthcare infrastructure, while Europe shows steady growth with a focus on innovative therapies. The Asia-Pacific region is a burgeoning market, propelled by large patient populations and improving healthcare access, alongside promising growth trends in Latin America and the Middle East.
• Major Investors: Major investors in the Pemphigus Vulgaris space are increasingly focusing on precision medicine and targeted immunotherapies. Large pharmaceutical firms, private equity groups, and venture capitalists are funding research into novel biological drugs and personalized treatment plans, moving away from traditional systemic corticosteroids. This investment shift highlights a commitment to developing safer, more effective long-term solutions for patients worldwide.
• Startup Ecosystem: The startup ecosystem is vibrant, with numerous biotech firms pioneering next-generation treatments. These agile companies leverage cutting-edge research to develop niche solutions, attracting substantial early-stage investment. Collaborations between these startups and established research institutions are accelerating clinical trials, fostering an environment ripe for innovation and the introduction of groundbreaking therapeutic approaches to the market.

How is AI Used in the Pemphigus Vulgaris Market?

Artificial intelligence (AI) developments have the potential to improve immuno-correlated dermatological pathology diagnosis, treatment, and evaluation. AI algorithms may be able to provide more objective results by avoiding the biases present in human diagnoses through careful design and debugging. Machine learning (ML) and deep learning (DL) are two popular AI algorithms; DL performs better on big datasets and intricate features.

Segmental Insights

Drug Class Insights

How Corticosteroids Dominated the Pemphigus Vulgaris Market in 2024?

The corticosteroids segment dominated the market in 2024. Pemphigus vulgaris is still best treated with systemic corticosteroids. Their use has reduced the mortality rate of an illness that was nearly always fatal to less than 10%. Prior to the availability of glucocorticosteroids in the 1950s, the death rate from pemphigus was between 60 and 90%.

Biologic Therapies

The biologic therapies segment is expected to grow at the fastest CAGR during the forecast period. Over the past ten years, rituximab, a chimeric anti-CD20 monoclonal antibody that targets B cells, has become a highly effective treatment for refractory pemphigus vulgaris. Numerous novel biologics have since been suggested or investigated for the treatment of autoimmune bullous disorders. Compared to traditional immunosuppressants, these may be more effective and cause fewer side effects.

Immunosuppressants

The immunosuppressants segment is expected to showcase lucrative growth during the forecast period. Patients with severe pemphigus vulgaris benefit from immunosuppressants (methotrexate, cyclophosphamide, and azathioprine) because they frequently lower the maintenance dose of prednisone needed following high-dosage prednisone treatment. Patients with pemphigus vulgaris in the early, stable stage benefit even more from immunosuppressants.

Treatment Type Insights

Why the First-Line Therapy Dominated the Pemphigus Vulgaris Market in 2024?

The first-line therapy segment dominated the market in 2024. Approved as a first-line treatment, rituximab successfully induces remission. Studies have shown that 90–95% of PV patients achieve disease control within ≤ 6 weeks of starting treatment, demonstrating the effectiveness of rituximab in inducing remission.

Combination Therapy

The combination therapy segment is expected to grow at the fastest CAGR during the forecast period. When treating pemphigus vulgaris, combination therapy typically combines an immunosuppressant such as rituximab, mycophenolate mofetil (MMF), cyclophosphamide, or methotrexate (MTX) with a corticosteroid such as prednisone. These combinations help reduce long-term side effects by enabling lower, more sustainable corticosteroid doses and accelerating remission.

Supportive & Symptomatic Therapy

The supportive & symptomatic therapy segment is expected to showcase lucrative growth during the forecast period. For Pemphigus vulgaris (PV), supportive and symptomatic therapy aims to control pain, encourage healing, and avoid complications like infections. The main benefits are enhancing the patient's immediate quality of life and making the primary systemic treatments more effective.

Route of Administration Insights

How did the Oral Segment Dominate the Pemphigus Vulgaris Market in 2024?

The oral segment dominated the market in 2024. The cornerstone of systemic therapy is oral medication, which is frequently used in conjunction with other oral immunosuppressants like mycophenolate mofetil or azathioprine to lessen long-term steroid side effects. Localized oral lesions can also be treated with topical steroids (pastes, mouthwashes).

Intravenous

The intravenous segment is expected to grow at the fastest CAGR during the forecast period. Fast-acting, immediate therapeutic effects can be achieved with intravenous drugs. For drugs that might not be absorbed by the GI tract, intravenous medications offer an alternative to the oral route. They are perfect for patients who have malabsorption or GI problems, as well as those who are unconscious or NPO (nothing by mouth).

Injectable

The injectable segment is expected to showcase lucrative growth during the forecast period. In a clinical setting, injections are preferred when oral administration would be ineffective, the medication must be administered quickly, or the dosage must be controlled. Injections are an essential tool in medical settings for administering drugs to the human body.

Distribution Channel Insights

How did the Hospital Pharmacies Dominate the Pemphigus Vulgaris Market in 2024?

The hospital pharmacies segment dominated the market in 2024. One of a hospital pharmacy's most crucial duties is distributing medications. It guarantees that the appropriate medication is administered to the appropriate patient at the appropriate time and dose. Healthcare workers' workflow efficiency is increased, medication safety is promoted, errors are decreased, and patient outcomes are improved through effective drug distribution. Hospital pharmacies use systematic distribution models based on clinical needs, staff availability, size, and technology.

Online Pharmacies

The online pharmacies segment is expected to grow at the fastest CAGR during the forecast period. By offering over-the-counter medications for common ailments, chatbots for immediate first aid, reviews of local doctors, and help in locating doctors, recommendations for labs for tests, home delivery of medications, explanations of the medications, etc., online/E-pharmacies are progressively taking over the role that local chemists have historically played.

Retail Pharmacies

The retail pharmacies segment is expected to showcase lucrative growth during the forecast period. Drugstores, supermarkets, and standalone stores are common locations for retail pharmacies, also known as community pharmacies, which cater to the general public. These pharmacies are easily accessible and provide a large selection of pharmaceuticals and health-related items.

End-User Insights

Why did the Hospitals Dominate the Pemphigus Vulgaris Market in 2024?

The hospitals segment dominated the market in 2024. When it comes to treating pemphigus vulgaris, hospitals, especially those with specialized dermatology or burn care units, offer several advantages. These include access to intensive therapy, a multidisciplinary approach, and cutting-edge treatment modalities that are challenging to administer in an outpatient setting.

Specialty Dermatology Clinics

The specialty dermatology clinics segment is expected to grow at the fastest CAGR during the forecast period. Because of their specialized knowledge, access to cutting-edge treatments, and all-encompassing, multidisciplinary approach to care, specialty dermatology clinics provide substantial benefits for the treatment of pemphigus vulgaris.

Research Institutes

The research institutes segment is expected to showcase lucrative growth during the forecast period. Pemphigus vulgaris is treated and studied by a number of prestigious international research institutes and medical facilities. These organizations frequently collaborate to explore new treatments and develop consensus guidelines.

Regional Insights

Which Factors Supported the Growth of North America in 2024?

North America dominated the pemphigus vulgaris market in 2024. supported by cutting-edge medical facilities, a high level of patient awareness, active research and development, a large supply of biologic treatments, and powerful government programs encouraging the treatment of uncommon diseases. Significant investments in healthcare, a robust pharmaceutical industry, and extensive insurance coverage all contribute to North America's dominance by ensuring patients have access to state-of-the-art treatments and diagnostics for pemphigus vulgaris.

Leading U.S. Pemphigus Vulgaris Management & Research

Immunosuppressive treatments, such as corticosteroids and rituximab, are the mainstay of Pemphigus vulgaris management in the U.S. These treatments are frequently directed by the American Academy of Dermatology guidelines. Leading institutions like the National Institutes of Health (NIH) and several university medical centers are conducting cutting-edge research, including clinical trials of new biologics and immunotherapies. The International Pemphigus & Pemphigoid Foundation (IPPF), which provides patient resources and links people to research advancements, can provide support and additional information.

Rapidly Growing Healthcare System is Driving the Asia Pacific

Asia Pacific is estimated to host the fastest-growing pemphigus vulgaris market during the forecast period due to the quickly expanding healthcare industry and the growing need for pemphigus vulgaris treatments. The region's biggest market is China. Growth in the Asia-Pacific area is being fueled by advancements in health technology and more financing for life sciences research. The Asia-Pacific region is the most lucrative due to more extensive government awareness campaigns and greater accessibility to generic drugs.

PUMCH Leads China's First Pemphigus Guideline

Improving pemphigus patient outcomes requires a clearly defined management protocol. Given this, the PUMCH Department of Dermatology has spearheaded the creation of China's first guidelines for the diagnosis and treatment of pemphigus. This guideline represents a major step forward in China's efforts to provide appropriate and more uniform pemphigus care. The Department of Dermatology at PUMCH provides comprehensive, high-quality outpatient care for bullous diseases, covering the full range of prevention, diagnosis, treatment, and follow-up. In order to give pemphigus patients more therapeutic options, the department is still dedicated to advancing research and encouraging consistent diagnosis and treatment.

Advancements in Biologics Development are Driving Europe

Europe is expected to grow at a significant CAGR in the pemphigus vulgaris market during the forecast period.    The demand for efficient PV treatments has increased due to the rising incidence and better diagnosis of autoimmune diseases. When compared to conventional corticosteroid-based treatments, biologic therapies offer more focused and efficient options.

Germany Leads Pemphigus Vulgaris Advanced Care in Europe

Germany provides state-of-the-art treatment for pemphigus vulgaris by combining cutting-edge research, novel treatments like rituximab, and all-encompassing patient support. For professional care and hope, visit clinical trials and specialized treatment facilities.

South America’s Growing Pemphigus Focus

South America is expected to grow significantly in the pemphigus vulgaris market during the forecast period. In South America, rising awareness of pemphigus vulgaris is driving improved diagnostic infrastructure and increasing adoption of biologic therapies. Urban dermatology centers in Brazil and Argentina are leading this shift, but access remains uneven across rural and under-resourced regions.

Argentina’s Pemphigus Progress Momentum

Argentina’s pemphigus vulgaris market is expanding with a stronger hospital-pharmacy network and growing preference for first-line treatments. Patients in metropolitan areas benefit from improved access, though outreach to more remote regions remains a key challenge for equitable care.

MEA Region’s Therapeutic Innovation Surge

The Middle East and Africa are expected to grow at a lucrative CAGR in the pemphigus vulgaris market during the forecast period. In the Middle East and Africa, investment in dermatology care and rare-disease treatment is fueling market growth. Key countries are increasingly using targeted biologics, and healthcare systems are strengthening, though regulatory and infrastructure gaps still need bridging.

GCC’s Pemphigus Treatment Breakthrough

Within the GCC, nations such as Saudi Arabia and the UAE are advancing pemphigus vulgaris research through specialized clinics and the rollout of biologics. Public health strategies and telemedicine are improving access, but high therapy costs continue to challenge universal adoption.

Pemphigus Vulgaris Market Value Chain Analysis

Research and Development (R&D): Finding possible targets, creating novel medications, and carrying out preliminary research in labs are all part of this first phase. Driven by an understanding of autoimmune mechanisms, it focuses on novel treatments such as cell therapies, small molecules, and biologics.

Companies: Cabaletta Bio Inc, HanAll Biopharma Co Ltd, Argenx SE, BioXpress Therapeutics SA, Octagon Therapeutics Inc, ImmunoWork LLC, and Daewoong Pharmaceutical Co Ltd

Clinical Trials and Regulatory Approvals: After a medication is created, it goes through extensive clinical testing to evaluate its effectiveness and safety. After that, a request for regulatory approval from organizations like the FDA is made, necessitating a thorough evaluation before going on sale.

Companies: Cabaletta Bio, Argenx SE, Roche (F. Hoffmann-La Roche Ltd), Dr. Reddy's Laboratories, Principia Biopharma, Genentech, Inc., and Kemia, Inc 

Distribution to Hospitals, Pharmacies: Distribution channels transfer the medication from producers to final consumers following approval. To guarantee patient access, this covers both hospital and retail pharmacies as well as internet pharmacies.

Companies: F. Hoffmann-La Roche Ltd, Pfizer Inc, AbbVie Inc, CSL Behring GmbH, Novartis AG, Teva Pharmaceutical Industries Ltd, and Johnson & Johnson Services, Inc.

Company Landscape

F. Hoffmann-La Roche Ltd. (Roche)

Corporate Information:

• Headquarters: Basel, Switzerland
• Year Founded: 1896
• Ownership Type: Publicly Traded (SIX Swiss Exchange: ROG)

History and Background:

• Founded by Fritz Hoffmann-La Roche, initially focusing on vitamin preparations and later expanding into pharmaceutical and diagnostic products.
• Became a pioneer in oncology and, more recently, a leader in personalized healthcare.

Key Milestones/Timeline:

• 1896: Company founding.
• Mid-20th Century: Major contributions to psychotropic drugs (e.g., Valium).
• 1990s-2000s: Emergence as a leader in oncology with products like Herceptin and Avastin.
• 2006: FDA approval of Rituximab (Rituxan/MabThera) for non-Hodgkin's lymphoma, later expanding to autoimmune conditions.
• 2018: FDA approval of Rituxan (rituximab) for the treatment of moderate to severe pemphigus vulgaris (PV) in adults, marking a major advancement.

Business Overview:

A global healthcare company with two main divisions: Pharmaceuticals and Diagnostics.

Business Segments/Divisions:

• Pharmaceuticals: Focuses on developing and commercializing therapeutic medicines, primarily in oncology, immunology, infectious diseases, and neuroscience.
• Diagnostics: Provides a broad portfolio of diagnostic solutions, including in vitro diagnostics, tissue diagnostics, and point-of-care testing.

Geographic Presence:

Global presence, with major operations in North America, Europe, Asia-Pacific, and emerging markets. North America is a significant revenue driver.

Key Offerings:

• Rituxan/MabThera (rituximab): Anti-CD20 monoclonal antibody (a cornerstone of PV treatment).
• Extensive portfolio in oncology, immunology (e.g., Ocrevus, Actemra), ophthalmology, and hematology.

End-Use Industries Served:

• Hospitals and Specialty Clinics
• Research Institutes and Laboratories
• Physician Offices/Ambulatory Surgical Centers

Key Developments and Strategic Initiatives:

• Mergers & Acquisitions: Continues to strategically acquire biotech companies to strengthen its pipeline in neuroscience, oncology, and immunology.
• Partnerships & Collaborations: Engages in numerous R&D collaborations with academic institutions and biotech firms to explore novel targets and digital health solutions.
• Product Launches/Innovations: Focus on next-generation biologics and subcutaneous formulations of existing intravenous therapies.
• Capacity Expansions/Investments: Ongoing investments in manufacturing capabilities for biologics and advanced diagnostic systems.
• Regulatory Approvals: Rituxan is the only FDA-approved biologic for PV. Continues to pursue approvals for new indications and novel molecules.

Distribution Channel Strategy:

Primarily focused on Hospital Pharmacies and Specialty Pharmacies due to the nature of complex biologic infusions and the requirement for specialized handling and administration (e.g., intravenous Rituximab).

Technological Capabilities/R&D Focus:

• Core Technologies/Patents: Expertise in monoclonal antibodies, small molecules, and personalized medicine platforms driven by advanced diagnostics.
• Research & Development Infrastructure: Robust global R&D network, with a high R&D spend focused on addressing high-unmet need areas like rare autoimmune diseases.
• Innovation Focus Areas: Personalized healthcare, leveraging real-world data and AI for drug discovery, and developing novel targeted therapies including FcRn inhibitors for autoimmune conditions.

Competitive Positioning:

• Strengths & Differentiators: The pioneer and market leader in anti-CD20 therapy for PV (Rituxan). Strong legacy and expertise in immunology and complex biologics. Integrated Pharmaceutical and Diagnostics divisions.
• Market presence & ecosystem role: Dominant player in the autoimmune and oncology markets globally. Sets the standard of care for anti-CD20 therapy.

SWOT Analysis:

• Strengths: Global leadership in biologics; established effectiveness and FDA approval of Rituxan for PV; large financial resources for R&D.
• Weaknesses: High cost of biologics; patent expiration and competition from biosimilars (e.g., Truxima, Ruxience).
• Opportunities: Further pipeline development in targeted PV therapies (e.g., FcRn inhibitors); expansion into emerging markets; utilizing diagnostics to improve PV patient identification.
• Threats: Aggressive competition from biosimilar manufacturers and novel therapeutic classes (e.g., BTK inhibitors, CAR-T).

Recent News and Updates (2024-2025):

• Press Releases (Example Focus): Continued communication regarding the use and efficacy of Rituximab in autoimmune disorders, including data presentations at major dermatology and rheumatology congresses in 2024.
• Industry Recognitions/Awards: Routinely recognized as a top global pharmaceutical company for innovation and R&D investment.

AbbVie Inc.

Corporate Information:

• Headquarters: North Chicago, Illinois, USA
• Year Founded: 2013 (Spun off from Abbott Laboratories)
• Ownership Type: Publicly Traded (NYSE: ABBV)

History and Background:

• Formed as a research-based pharmaceutical company specializing in complex biologic medicines, separating from Abbott Laboratories to focus on biopharma.
• Inherited the blockbuster drug Humira (adalimumab), establishing a dominant position in the immunology market.

Key Milestones/Timeline:

• 2013: Spin-off from Abbott Laboratories.
• Early 2010s: Focus on growing the immunology franchise with Humira.
• 2019: Acquired Allergan, significantly expanding its portfolio into neuroscience and aesthetics.
• 2023-2024: Faced the loss of exclusivity for Humira in the US, leading to a strong focus on next-generation immunology drugs and biosimilar strategies.
• 2024-2025: Increased focus on expanding its biosimilar presence for key biologics, including Rituximab biosimilars, in various global markets.

Business Overview:

A global biopharmaceutical company dedicated to developing and commercializing advanced therapies across key therapeutic areas.

Business Segments/Divisions:

• Immunology: Core focus area, including treatments for rheumatoid arthritis, psoriasis, Crohn's disease, and other autoimmune conditions.
• Oncology: Products for various cancers.
• Neuroscience: Treatments for diseases like migraine and movement disorders (expanded via Allergan acquisition).
• Aesthetics: (Allergan Aesthetics)

Geographic Presence:

Significant global footprint, with major revenues from the United States and strong presence across Europe, Asia-Pacific, and Latin America.

Key Offerings:

• Rituximab Biosimilars: Key to their presence in the PV market, competing with Roche's branded Rituxan.
• Humira (adalimumab): TNF inhibitor (though not approved for PV, it dominates the autoimmune market).
• Skyrizi (risankizumab) & Rinvoq (upadacitinib): Next-generation immunology products.

End-Use Industries Served:

• Hospitals and Specialty Clinics
• Retail and Specialty Pharmacies
• Managed Care Organizations

Key Developments and Strategic Initiatives:

• Mergers & Acquisitions: The large-scale acquisition of Allergan (2019) diversified its portfolio. Focused on smaller, strategic acquisitions to bolster its pipeline.
• Partnerships & Collaborations: Collaborations for drug discovery and pipeline development, particularly in immunology and oncology.
• Product Launches/Innovations: Heavy investment in launching and scaling next-generation immunology drugs (Skyrizi, Rinvoq) and launching biosimilars to maintain market share.
• Capacity Expansions/Investments: Investment in manufacturing and R&D to support the growth of its new immunology and oncology pipelines.
• Regulatory Approvals: Securing approvals for new immunology products in various indications and geographies. Actively promoting biosimilars for Rituximab globally.

Distribution Channel Strategy:

• Leverages a robust Specialty Pharmacy and Retail Pharmacy network for self-administered products like Humira, Skyrizi, and Rinvoq.
• Uses Hospital/Infusion Center channels for intravenous biosimilars of Rituximab.

Technological Capabilities/R&D Focus:

• Core Technologies/Patents: Expertise in monoclonal antibodies (TNF, IL-23, JAK inhibition), small molecule development, and biosimilar manufacturing.
• Research & Development Infrastructure: Major R&D centers globally, with significant investment in developing immunology and oncology assets.
• Innovation Focus Areas: Developing therapies with improved dosing and efficacy for complex autoimmune disorders, and maintaining a leadership position in immunology post-Humira loss of exclusivity.

Competitive Positioning:

• Strengths & Differentiators: Global leader in immunology (historically Humira). Strong commercial infrastructure and deep expertise in autoimmune markets. Aggressive strategy in the biosimilar space to capture market share from branded biologics like Rituxan.
• Market presence & ecosystem role: High market access and established relationships with payers and healthcare providers due to its legacy in immunology. A key driver in the biosimilar segment of the PV market.

SWOT Analysis:

• Strengths: Leading immunology portfolio; diversified therapeutic areas; strong global commercial presence.
• Weaknesses: Major revenue risk due to Humira biosimilar competition; reliance on a few blockbuster drugs.
• Opportunities: Growth of next-generation immunology assets (Skyrizi, Rinvoq); increasing market penetration of its Rituximab biosimilar to compete directly in the PV market.
• Threats: Competition from novel PV therapies (e.g., CAR-T, FcRn inhibitors); aggressive pricing from other biosimilar manufacturers.

Recent News and Updates (2024-2025):

• Press Releases (Example Focus): Announcements in early 2024 regarding the successful commercial launch and increased market share of its biosimilars in ex-US markets. Continued positive Phase III data announcements for next-generation immunology drugs.
• Industry Recognitions/Awards: Recognized for best-in-class product portfolios and patient support programs in the immunology space.

Top Vendors in the Pemphigus Vulgaris Market & Their Offerings

Top Companies in the Pemphigus Vulgaris Market

• Pfizer Inc.
• F. Hoffmann-La Roche Ltd. 
• Sanofi 
• Amgen Inc.
• GlaxoSmithKline plc (GSK)
• Novartis AG
• AstraZeneca
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Argenx SE
• Cabaletta Bio Inc.
• Daewoong Pharmaceutical Co. Ltd.
• HanAll Biopharma Co. Ltd.
• Merck & Co., Inc.
• GRIFOLS SA
• Boehringer Ingelheim International GmbH
• Regeneron Pharmaceuticals Inc.
• Johnson & Johnson Services, Inc.
• Zydus Group
• Alexion Pharmaceuticals

Recent Developments in the Pemphigus Vulgaris Market

• In October 2025, initial dose data from the RESET-PVTM trial, which evaluated rese-cel (resecabtagene autoleucel, formerly known as CABA-201) at 1 x 106 cells/kg without preconditioning in three evaluable patients with pemphigus vulgaris (PV), were presented by Cabaletta Bio, Inc., a clinical-stage biotechnology company dedicated to creating and introducing the first curative targeted cell therapies specifically for patients with autoimmune diseases.
• In March 2025, the Japanese Ministry of Health, Labour, and Welfare has approved Chugai (a subsidiary of Roche) and Zenyaku Kogyo's co-marketed Rituxan® (rituximab) for children with "frequently relapsing or steroid-dependent nephrotic syndrome" (IV injection, 100 mg and 500 mg) that is not yet incurable.

Segments Covered in the Report

By Drug Class 

• Corticosteroids
• Immunosuppressants
• Biologic Therapies 
• Intravenous Immunoglobulin (IVIG)
• Plasmapheresis/Plasma Exchange

By Treatment Type

• First-Line Therapy
• Second-Line Therapy
• Combination Therapy
• Supportive & Symptomatic Therapy

By Route of Administration

• Oral
• Injectable
• Intravenous

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End-User

• Hospitals
• Specialty Dermatology Clinics
• Research Institutes

By Region

• North America
  • U.S.
  • Canada
  • Mexico
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe
  • Western Europe
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
• Eastern Europe 
  • Austria
  • Russia & Belarus
  • Türkiye
  • Albania
  • Rest of Eastern Europe
• Asia Pacific
  • China
  • Taiwan
  • India
  • Japan
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• MEA 
  • GCC Countries
  • Saudi Arabia
  • United Arab Emirates (UAE)
  • Qatar
  • Kuwait
  • Oman
  • Bahrain
• South Africa
• Egypt
• Rest of MEA